0000000000345026

AUTHOR

Peter A. Raven

showing 3 related works from this author

Magnetically-actuated drug delivery device (MADDD) for minimally invasive treatment of prostate cancer: An in vivo animal pilot study

2017

Background The vast majority of prostate cancer presents clinically localized to the prostate without evidence of metastasis. Currently, there are several modalities available to treat this particular disease. Despite radical prostatectomy demonstrating a modest prostate cancer specific mortality benefit in the PIVOT trial, several novel modalities have emerged to treat localized prostate cancer in patients that are either not eligible for surgery or that prefer an alternative approach. Methods Athymic nude mice were subcutaneously inoculated with prostate cancer cells. The mice were divided into four cohorts, one cohort untreated, two cohorts received docetaxel (10 mg/kg) either subcutaneo…

MaleOncologymedicine.medical_specialtyUrologymedicine.medical_treatmentMice NudeAntineoplastic AgentsDocetaxel02 engineering and technologyMetastasisMice03 medical and health sciencesProstate cancerDrug Delivery Systems0302 clinical medicineProstateIn vivoInternal medicinemedicineAnimalsMinimally Invasive Surgical ProceduresProstatectomybusiness.industryProstatectomyProstatic NeoplasmsProstate-Specific Antigen021001 nanoscience & nanotechnologymedicine.diseaseTumor BurdenSurgeryTreatment Outcomemedicine.anatomical_structureOncologyDocetaxel030220 oncology & carcinogenesisCohortMagnetsImmunohistochemistryTaxoidsDrug Monitoring0210 nano-technologybusinessmedicine.drugThe Prostate
researchProduct

Orthotopic Mouse Models of Urothelial Cancer

2017

Orthotopic mouse models of urothelial cancer are essential for testing novel therapies and molecular manipulations of cell lines in vivo. These models are either established by orthotopic inoculation of human (xenograft models) or murine tumor cells (syngeneic models) in immunocompromised or immune competent mice. Current techniques rely on inoculation by intravesical instillation or direct injection into the bladder wall. Alternative models include the induction of murine bladder tumors by chemical carcinogens (BBN) or genetic engineering (GEM).

0301 basic medicinebusiness.industry03 medical and health sciences030104 developmental biology0302 clinical medicineImmune systemMurine tumorCell cultureIn vivo030220 oncology & carcinogenesisChemical carcinogensIntravesical instillationCancer researchMedicineUrothelial cancerbusiness
researchProduct

Inhibition of GLI2 with antisense-oligonucleotides: A potential therapy for the treatment of bladder cancer.

2019

The sonic hedgehog (SHH) signaling pathway plays an integral role in the maintenance and progression of bladder cancer (BCa) and SHH inhibition may be an efficacious strategy for BCa treatment. We assessed an in-house human BCa tissue microarray and found that the SHH transcription factors, GLI1 and GLI2, were increased in disease progression. A panel of BCa cell lines show that two invasive lines, UM-UC-3 and 253J-BV, both express these transcription factors but UM-UC-3 produces more SHH ligand and is less responsive in viability to pathway stimulation by recombinant human SHH or smoothened agonist, and less responsive to inhibitors including the smoothened inhibitors cyclopamine and SANT-…

0301 basic medicineanimal structuresCyclopaminePhysiologyCell Survivalmedicine.medical_treatmentClinical BiochemistryAntineoplastic AgentsZinc Finger Protein Gli2Targeted therapy03 medical and health scienceschemistry.chemical_compound0302 clinical medicineGLI1GLI2Cell Line TumormedicineHumansSonic hedgehogskin and connective tissue diseasesTranscription factorbiologyChemistryCell CycleNuclear ProteinsCell Biology3. Good healthGene Expression Regulation Neoplastic030104 developmental biologyUrinary Bladder Neoplasms030220 oncology & carcinogenesisbiology.proteinCancer researchSignal transductionSmoothenedJournal of cellular physiology
researchProduct